

**Cooley Godward LLP**

ATTORNEYS AT LAW

**FAX**

THIS FACSIMILE AND THE INFORMATION IT CONTAINS ARE INTENDED TO BE A CONFIDENTIAL COMMUNICATION ONLY TO THE PERSON OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US BY TELEPHONE AND RETURN THIS ORIGINAL FAX TO THIS OFFICE BY MAIL.

Five Palo Alto Square  
3000 El Camino Real  
Palo Alto, CA  
94306-2155

Offices:  
Broomfield, CO  
Palo Alto, CA  
Reston, VA  
San Diego, CA  
San Francisco, CA

MAIN (650) 843-5000  
FAX (650) 857-0663

DATE: March 11, 2003

PLEASE DELIVER TO:	PHONE NO.:	FAX NO.:
Examiner M. Schmidt	(703) 308-4471	(703) 746-5264

FROM: Roberta L. Robins

PHONE: (650) 843-5589

REPLY FAX: (650) 857-0663

RE:

NUMBER OF PAGES, INCLUDING COVER PAGE: 4	Client Number: 018584-2095
Originals Will Not Follow	Requestor #:

**MESSAGE:**

RE: USSN 09/706,580

See enclosed version with marking to show changes made.

TO BE MADE OF OFFICIAL RECORD

If you do not receive all of the pages, please call  
Sender's Name at Sender's Phone Number as soon as possible.

Received from &lt;6508570663&gt; at 3/11/03 1:19:50 PM [Eastern Standard Time]

Version with markings to show changes made

Claims 24, 26, 32 and 35 have been amended as follows:

24. (Twice amended) A method of inducing gene expression in a mammalian cell, said method comprising:

(a) transducing the mammalian cell *in vivo* with (i) a first recombinant adeno-associated virus (AAV) virion comprising an AAV vector that comprises a transcriptional promoter region operably linked to a polynucleotide of interest, wherein the transcriptional promoter region comprises at least one ecdysone-responsive element (EcRE), and a promoter capable of directing the *in vivo* transcription of said polynucleotide of interest in a mammalian cell, located downstream of the at least one EcRE; and (ii) a second recombinant AAV virion comprising an AAV vector that comprises a coding sequence encoding an ecdysone receptor (EcR) and further comprises a coding sequence encoding a retinoid-X-receptor (RXR), wherein said EcR and RXR coding sequences are operably linked to control elements capable of directing the *in vivo* transcription thereof in the mammalian cell; and

(b) providing ecdysone, or an analog thereof capable of binding the EcR, to said mammalian cell *in vivo*, in an amount sufficient to induce expression of the polynucleotide of interest.

26. (Amended) A method of inducing gene expression in a mammalian cell, said method comprising:

(a) transducing the mammalian cell *in vivo* with (i) a first recombinant adeno-associated virus (AAV) virion comprising an AAV vector that comprises a transcriptional promoter region operably linked to a polynucleotide of interest, wherein the transcriptional promoter region comprises five ecdysone-responsive elements positioned upstream of a heat shock protein (Hsp) promoter sequence, wherein the transcriptional promoter region is capable of directing the *in vivo* transcription of said polynucleotide of interest in a mammalian cell; (ii) a second recombinant AAV virion comprising an AAV vector that comprises a coding sequence encoding an ecdysone receptor (EcR) operably linked to control elements capable of directing the *in vivo*

Attorney Docket No. 0800-0022  
Serial No.: 09/706,580

transcription of said EcR coding sequence in a mammalian cell; and (iii) a third recombinant AAV virion comprising an AAV vector that comprises a coding sequence encoding a retinoid-X-receptor (RXR) operably linked to control elements capable of directing the *in vivo* transcription of said RXR coding sequence in the mammalian cell; and

(b) providing ponasterone A to said mammalian cell *in vivo*, in an amount sufficient to induce expression of the polynucleotide of interest.

32. (Amended) A method of inducing gene expression in a mammalian cell, said method comprising:

(a) transducing the mammalian cell *in vivo* with (i) a first recombinant adeno-associated virus (AAV) virion comprising an AAV vector that comprises a transcriptional promoter region operably linked to a polynucleotide of interest, wherein the transcriptional promoter region comprises at least one ecdysone-responsive element (EcRE), and a promoter capable of directing the *in vivo* transcription of said polynucleotide of interest in a mammalian cell, located downstream of the at least one EcRE; (ii) a second recombinant AAV virion comprising an AAV vector that comprises a coding sequence encoding an ecdysone receptor (EcR) operably linked to control elements capable of directing the *in vivo* transcription thereof in the mammalian cell; and (iii) a third recombinant AAV virion comprising an AAV vector that comprises a coding sequence encoding a retinoid-X-receptor (RXR) operably linked to control elements capable of directing the *in vivo* transcription thereof in the mammalian cell; and

(b) providing ecdysone, or an analog thereof capable of binding the EcR, to said mammalian cell *in vivo*, in an amount sufficient to induce expression of the polynucleotide of interest.

35. (Amended) A method of inducing gene expression in a mammalian cell, said method comprising:

(a) transducing a mammalian cell *in vivo* comprising a retinoid-X-receptor (RXR) with (i) a first recombinant adeno-associated virus (AAV) virion comprising an AAV vector that comprises a transcriptional promoter region operably linked to a polynucleotide of interest, wherein the transcriptional promoter region comprises at least one ecdysone-responsive element

Attorney Docket No. 0800-0022  
Serial No.: 09/706,580

(EcRE), and a promoter capable of directing the *in vivo* transcription of said polynucleotide of interest in a mammalian cell, located downstream of the at least one EcRE and (ii) a second recombinant AAV virion comprising an AAV vector that comprises a coding sequence encoding an ecdysone receptor (EcR) operably linked to control elements capable of directing the *in vivo* transcription thereof in the mammalian cell; and

(b) providing ecdysone, or an analog thereof capable of binding the EcR, to said mammalian cell *in vivo*, in an amount sufficient to induce expression of the polynucleotide of interest.